CytomX Therapeutics, Inc.

CytomX Therapeutics Beats on EPS, Stock Up 3.16%

CytomX Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 3.16%. However, the lack of revenue figures and guidance leaves some uncertainty about the company's future performance. Investors may be cautiously optimistic based on the EPS beat, but the absence of additional context from management is notable.